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Abstract
Oxidative stress and glutathione (GSH) depletion are implicated in mycocystin hepatotoxicity. To investigate the role of
nuclear factor erythroid 2-related factor 2 (Nrf2) in microcystin-induced liver injury, Nrf2-null, wild-type, and Keap1-
hepatocyte knockout (Keap1-HKO) mice were treated with microcystin (50 mg/kg, i.p.). Blood and liver samples were
collected 8 h thereafter. Microcystin increased serum alanine aminotransferase and aspartate aminotransferase activities,
and caused extensive inflammation and necrosis in Nrf2-null and wild-type mice, but not in Keap1-HKO mice. Oxidative
stress and inflammation are implicated in microcystin-induced hepatotoxicity, as evidenced by increased lipid peroxidation
and increased expression of pro-inflammatory genes, such as neutrophil-specific chemokines mKC and MIP-2, and pro-
inflammatory cytokines IL-1b and IL-6. The increased expression of these pro-inflammatory genes was attenuated in Keap1-
HKO mice. Nrf2 and Nqo1 mRNA and protein were higher in Keap1-HKO mice at constitutive levels and after microcystin. To
further investigate the mechanism of the protection, hepatic GSH and the mRNA of GSH-related enzymes were determined.
Microcystin markedly depleted liver GSH by 60–70% in Nrf2 and WT mice but only 35% in Keap1-HKO mice. The mRNAs of
GSH conjugation and peroxide reduction enzymes, such as Gsta1, Gsta4, Gstm, and Gpx2 were higher in livers of Keap1-HKO
mice, together with higher expression of the rate-limiting enzyme for GSH synthesis (Gclc). Organic anion transport
polypeptides were increased by microcystin with the most increase in Keap1-HKO mice. In conclusion, this study
demonstrates that higher basal levels of Nrf2 and GSH-related genes in Keap1-HKO mice prevented microcystin-induced
oxidative stress and liver injury.
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Introduction
Contamination of natural water by cyanobacterial bloom is a
worldwide problem, causing public health hazards to humans and
livestock [1,2]. Microcystins, a family of cyclic heptapeptides, are
the most common and potent toxins associated with cyanobacteria
[3]. Microcystin toxicity has been implicated in liver necrosis,
hepatic failure, and liver cancer [4]. The first phase of damage is
initiated by the binding of microcystins to sulfhydryls of
glutathione (GSH) and proteins, resulting in the generation of
reactive oxygen species (ROS) and protein inactivation [5].
Microcystin-induced ROS in turn produce lipid peroxidation
and DNA damage [5].
Sulforaphane is an activator of Nrf2 [6] and has been shown to
protect against microcystin-induced toxicity to liver cells [7] and
livers of mice [6,7], probably mediated through the activation of
Nrf2. Microcystins are known to be detoxified by glutathione to
form glutathione conjugates [8–10], catalyzed by GSH S-
transferases in laboratory animals [10] and in humans [11]. Thus,
any means that increases cellular GSH and GSH conjugation
should be beneficial to protect against microcystin toxicity.
Nuclear factor erythroid 2-related factor 2 (Nrf2) is a major
defense mechanism against oxidative and/or electrophilic stress in
the liver [12]. Nrf2 is bound by kelch-like ECH associating protein
1 (Keap1) in the cytosol [13]. Genetically knock-down of Keap1
(Keap1-Kd) results in mice with Nrf2 activation throughout the
body [14]. By crossing Keap1-Kd mice and AlbCre+ mice, which
express Cre only in hepatocytes, Keap1-hepatocyte knockout
(Keap1-HKO) mice with maximum Nrf2 activation in liver were
generated [15–17]. Genetic Nrf2 activation in turn enhances the
expression of cytoprotective genes/proteins that catalyze GSH
synthesis (Gclc), GSH peroxidase (Gpx), GSH conjugation
reactions (Gst), oxidized GSH and other SH-protein repair genes;
Genetic Nrf2 activation also increases the expression of
NAD(P)H:quinone oxidoreductase 1 (Nqo1) and increases the
mRNA expression of hepatic Mrp transporters [15,17]. We have
used this genetic Nrf2 ‘‘gene-dose’’ model to examine the effect of
Nrf2 activation on the hepatotoxicity of 13 chemicals. Nrf2 has
shown to protect against the hepatotoxicity produced by 10 of the
hepatotoxicants including microcystin [18], but the underlining
mechanisms remain to be elucidated.
Thus, the purpose of the present study was to determine the role
of constitutive activation of Nrf2 in the protection against
microcystin acute toxicity using the Nrf2 ‘‘gene dose–response’’
model, focusing on hepatic GSH, GSH conjugation, as well as
oxidized GSH and SH-protein reducing enzymes.
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Materials and Methods
Reagents
Microcystin (Microcystin-LA) was purchased from Sigma-
Aldrich (St. Louis, MO). All other chemicals were reagent grade
and commercially available.
Animals
Nrf2-null mice were obtained from Dr. Jefferson Chan
(University of California, Irvine, CA) [19], the genetic background
C57BL/6 mice were purchased from Charles River Laboratories,
Inc. (Wilmington, MA), and Keap1-HKO mice [15,17] were
backcrossed at least eight generations and shown to be congenic by
Jackson Laboratories. Mice were housed in a temperature-, light-,
and humidity-controlled facilities and had free access to standard
rodent chow and water ad libitum. Animal care was provided in
Figure 1. (Top) presents serum alanine aminotransferase (ALT), (Bottom) serum aspartate aminotransferase (AST) in Nrf2-null,
wild-type and Keap1-HKO mice administered saline (10 ml/kg, i.p.) or microcystin (50 mg/kg, i.p.). Values are expressed as mean 6
S.E.M. (n = 7–10). *Significantly different from the basal level of the same genotype (p # 0.05); #Significantly different from Nrf2-null mice treated
with microcystin (p # 0.05).
doi:10.1371/journal.pone.0093013.g001
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accordance with the US Public Health Policy on the Care and Use
of Animals, and the study protocol was approved by the
Institutional Animal Care and Use Committee of the University
of Kansas Medical Center.
Experimental Design
Nrf2-null mice, wild-type mice, and Keap1-HKO mice were
treated with either microcystin-LA (50 mg/kg, i.p.) or saline
(10 ml/kg, i.p.). Blood and livers were collected 8 hrs thereafter.
Portions of livers were fixed in 10% neutral formalin for
histological analysis, and others were frozen in liquid nitrogen
and stored at 280uC. The dose and time selection were based on
our previous publication [20] and pilot experiments.
Hepatotoxicity Evaluation
Blood was placed on ice for 60 min and centrifuged (8000 g,
10 min) to prepare serum. Serum samples were analyzed by
standard enzymatic assays using commercial kits for alanine
aminotransferase (Infinity ALT) and aspartate aminotransferase
(Infinity AST, Thermo Scientific, Middletown, VA) as indicators
of hepatotoxicity.
Histopathology
A portion of each liver was fixed in 10% neutral formalin,
processed by standard histological techniques, and stained with
hematoxylin and eosin (H&E). and evaluated for hepatocellular
necrosis with a Zeiss microscope.
Lipid Peroxidation
Lipid peroxidation in livers was determined by quantifying
thiobarbituric acid reactive substances (TBARS), using malon-
dialdehyde (MDA) as the standard (Thermo Fisher Scientific Inc.,
Fair Lawn, NJ).
Quantification of GSH Concentrations
The concentrations of reduced glutathione (GSH) were
estimated by total thiol levels in livers of mice using a 5,59-
dithiobis-2-nitrobenzoic acid assay and the thionitrobenzene
formed was quantified spectrophotometrically using a GSH assay
kit (CS0260) from Sigma (St Louis, MO).
Total RNA Isolation and RT-PCR
Total RNA was isolated using RNAzol B reagent (Tel-Test,
Inc., Friendswood, TX) and quantified spectrophotometrically at
260 nm. The quality of RNA samples were evaluated by 260/280
ratios (.1.8). Total RNA was reverse-transcribed into cDNA by a
High Capacity RT Kit (Applied Biosystems, Foster City, CA), and
amplified with Power SYBR Green PCR Master Mix in a
7900HT PCR System (Applied Biosystems, Foster City, CA).
Oligonucleotide primers were designed with Primer3 software,
and are listed in Table S1. The expression of genes was calculated
by the 22DDCt method, normalized to the house-keeping gene
G3PDH, and expressed as relative expression of%G3PDH.
Western Blot Analysis
Liver protein was extracted with a T-PER tissue protein
extraction kit (Thermo Scientific, Rockford, IL) with freshly
prepared proteinase inhibitors (Sigma, St. Louis, MO). Protein
concentrations were determined using a BCA protein assay
according to the manufacturer’s instructions (Thermo Scientific,
Rockford, IL). Approximately 40 mg of cytosolic protein was used
for immunoblotting proteins of interest. The primary antibodies
used in this study include Gclc (sc-27688) from Santa Cruz
Biotechnology (Santa Cruz, CA), whereas Nqo1 (Ab2346) and b-
actin (Ab8227) were from Abcam (Cambridge, MA). Secondary
antibodies were purchased from Sigma-Aldrich (St. Louis, MO).
Protein-antibody complexes were detected using an enhanced
chemiluminescent kit (Thermo Scientific, Rockford, IL) and
exposed to HyBlot CL autoradiography film (Denville Scientific
Inc., Metuchen, NJ).
Statistical Analysis
Data are expressed as mean 6 SEM and analyzed using a one-
way ANOVA followed by Duncan’s multiple range test utilizing
SPSS 13 Software (SAS, NC). The significant level was set at p #
0.05.
Results
Nrf2 Protects Against Hepatotoxicity of Microcystin
Microcystin-induced acute hepatotoxicity was indicated by
increased serum enzyme activities of alanine aminotranferase
(ALT) and aspartate aminotrasferase (AST). In saline-treated mice,
serum ALT and AST activities in Nrf2-null, wild-type, and
Keap1-HKO mice were low, without differences between
genotypes. Microcystin increased serum ALT activities 45-fold in
Nrf2-null mice, 42-fold in wild-type mice, but only 5.4-fold in in
Keap1-HKO mice (Figure 1, top). Serum AST activities of Nrf2-
null, wild-type, and Keap1-HKO mice showed a similar pattern,
that is, microcystin increased serum AST activities 47-fold in Nrf2-
null mice, 45-fold in wild-type mice, but only 7.5-fold in Keap1-
HKO mice (Figure 1, bottom).
Liver histopathology. There were no observable abnormal-
ities in the livers of control Nrf2-null, wild-type, and Keap1-HKO
mice (data not shown). However, microcystin produced severe
hemorrhage, inflammation and extensive necrosis in Nrf2-null
mice as we observed earlier [20]. Similar lesions were also evident
in wild-type mice, but to a lesser extent. In comparison, only mild
Figure 2. Histological analysis of livers from Nrf2-null, wild-type, and Keap1-HKO mice treated with microcystin (50 mg/kg, i.p.). H &
E staining with magnification (2006).
doi:10.1371/journal.pone.0093013.g002
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hepatocyte swelling was evident in Keap1-HKO mice (Figure 2),
and no apparent necrosis was observed.
Nrf2 Prevented GSH Depletion and Reduced Microcystin-
induced Lipid Peroxidation
Microcystin has been reported to produce a decrease of GSH in
the liver as early as 2 hrs [10] and ROS generation within 12 hrs
after exposure [5]. Thus, both hepatic GSH and lipid peroxidation
levels were quantified.
GSH. The basal GSH concentrations in liver tended to be
higher in mice with graded Nrf2 activation. After microcystin
injection, the hepatic GSH concentrations decreased by 70% in
Nrf2-null mice, 64% in wild-type mice, but only 35% in Keap1-
HKO mice, when compared to their corresponding controls
(Figure 3, left panel).
TBARS. Figure 3, right panel, shows the amount of lipid
peroxidation, as determined by thiobarbiturate reactive substances
(TBARS), using malondialdehyde (MDA) as the standard, in the
Figure 3. (Left) Hepatic glutathione concentrations (GSH), (Right) hepatic malondialdehyde (MDA) levels in Nrf2-null, wild-type and
Keap1-HKO mice administered saline (10 ml/kg, i.p.) or microcystin (50 mg/kg, i.p.). Values are expressed as mean 6 S.E.M. (n = 5–8).
*Significantly different from the basal level of the same genotype (p # 0.05); #Significantly different from Nrf2-null mice treated with microcystin (p
# 0.05).
doi:10.1371/journal.pone.0093013.g003
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livers of the various groups of mice. Microcystin increased hepatic
MDA levels 117% in Nrf2-null mice, 82% in WT mice, and 24%
in the Keap1-HKO mice.
Gene Expression Analysis
Nrf2-target genes Nqo1 and Gclc. To determine the
mechanism of how Nrf2 protects against microcystin-induced
Figure 4. (Top) The mRNA levels of NAD(P)H quinone oxidoreductase 1 (Nqo1) and glutamate-cysteine ligase, catalytic subunit
(Gclc) in Nrf2-null, wild-type and Keap1-HKO mice administered saline (10 ml/kg, i.p.) or microcystin (50 mg/kg, i.p.). Livers were
removed 8 h after microcystin and mRNA quantified by RT-PCR. Values are expressed as mean 6 S.E.M. (n = 8). *Significantly different from the basal
level of the same genotype (p # 0.05); #Significantly different from Nrf2-null mice treated with microcystin (p # 0.05). Representative Western-blot
analysis of Nqo1 and Gclc proteins inserted into mRNA expression graphs. Nqo1 and Gclc were higher in Keap1-HKO mice at both basal levels and
after microcystin.
doi:10.1371/journal.pone.0093013.g004
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toxicity, expression of the Nrf2-target genes NAD(P)H quinone
oxidoreductase 1 (Nqo1) and glutamate-cysteine ligase, catalytic
subunit (Gclc) were quantified in livers of Nrf2-null, wild-type, and
Keap1-HKO mice (Figure 4). The basal levels (% of G3PDH) of
Nqo1 were 0.137, 0.293 and 3.173 for Nrf2-null, WT, and Keap1-
HKO mice, respectively. Eight hours after microcystin adminis-
tration, mRNA of Nqo1 increased to 0.281, 1.402 and 11.63 for
Nrf2-null, WT, and Keap1-HKO mice, respectively. The basal
levels of Gclc were 3.843, 8.825 and 27.24 for Nrf2-null, WT, and
Keap1-HKO mice, respectively; Eight hours after microcystin
administration, mRNA of Gclc increased to 13.63, 26.08 and
86.89 for the Nrf2-null, WT, and Keap1-HKO mice, respectively,
indicating that Nrf2-targeted genes Nqo1 and Gclc were increased
after microcystin in a ‘‘gene-dose’’ manner.
The representative western-blot analysis of Nqo1 and Gclc
protein expression was inserted into Figure 4. Consistent with gene
expression analysis, the expression of Nqo1 and Gclc proteins were
highest in Keap1-HKO mouse livers, both before and after
microcystin intoxication.
Chemokine genes. mRNA levels of neutrophil-specific
chemokine macrophage inflammatory protein 2 (MIP-2) and
mouse keratinocyte-derived chemokine (mKC) are shown in
Figure 5, left panel. There were no differences in basal expression
of MIP-2 (around 0.03% of G3PDH) among the three genotypes.
Eight hours after microcystin administration, the mRNA of MIP-2
increased 45-fold, 37-fold, and 5.5-fold for the Nrf2-null, WT, and
Keap1-HKO mice, respectively. There were also no differences in
basal expression of mKC (around 1% of G3PDH) among the three
genotypes. Eight hours after microcystin administration, the
mRNA of mKC increased 14-fold, 12-fold, and 4-fold for Nrf2-
null, WT, and Keap1-HKO mice, respectively, indicating that
Nrf2-overexpression attenuated the microcystin-induced inflam-
matory response in a ‘‘gene-dose’’ manner.
Pro-inflammatory cytokine genes. The mRNA levels of
pro-inflammatory genes interleukin-1b (IL-1b) and IL-6 are shown
in Figure 5, right panel. There were no differences among the
three genotypes in the basal expression of IL-1b (0.04% of
G3PDH). Microcystin markedly increased the mRNA of IL-1b by
12-fold in Nrf2-null mice, 10-fold in WT mice, and 3-fold in
Keap1-HKO mice. There were no differences among the three
genotypes in the basal expression of IL-6 (0.002% of G3PDH).
Microcystin increased the mRNA of IL-6 20-fold in Nrf2-null and
WT mice, and only 3-fold in Keap1-HKO mice. Similar results
were evident for tumor necrosis factor alpha (TNFa) (data not
shown). These data indicate that constitutive Nrf2 activation
attenuated microcystin-induced hepatic inflammation.
In accordance with the inflammatory response, the expression
of the acute phase proteins Ho-1 (Heme oxygenase 21) and Egr1
(Early growth response protein 1) were also increased more in
Nrf2-null and wild-type mice than in Keap1-HKO mice (Figure 6).
Genes involved in GSH conjugation and peroxide
reduction. The mRNAs of enzymes involved in GSH conju-
gation and peroxide reduction before and after microcystin
administration are shown in Figure 7 (Gsta1, Gsta4 and Gtsm
for GSH conjugation and Gpx2 for peroxide reduction). In
general, the mRNA for these GSH transferase enzymes in the
basal condition were expressed at low levels, but markedly induced
by microcystin. Consistent with our recent publication (Wu et al.,
2012b), much higher basal expression was seen in Keap1-HKO
mice compared to Nrf2-null mice for Gsta1(113-fold), Gsta4 (5.3-
fold), Gstm (77-fold) and Gpx2 (108-fold). Microcystin further
increased the expression of these genes, but larger increases were
evident in Keap1-HKO mice compared to Nrf2-null mice for
Gsta1(39-fold), Gsta4 (33-fold), Gtsm (48-fold) and Gpx2 (6.2-fold).
Figure 5. The mRNA levels of neutrophil-specific chemokine
macrophage inflammatory protein 2 (MIP-2), mouse keratino-
cyte-derived chemokine (mKC), inflammation genes interleu-
kin-1b (IL-1b) and IL-6 in Nrf2-null, wild-type and Keap1-HKO
mice administered saline (10 ml/kg, i.p.) or microcystin (50 mg/
kg, i.p.). Livers were removed 8 h after microcystin and mRNA
quantified by RT-PCR. Values are expressed as mean 6 S.E.M. (n = 8).
*Significantly different from the basal level of the same genotype (p #
0.05); #Significantly different from Nrf2-null mice treated with
microcystin (p # 0.05).
doi:10.1371/journal.pone.0093013.g005
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The expression of these genes in wild-type mice was between that
in Nrf2-null and Keap1-HKO mice. Thus, the induction of Gsts is
apparently a major defense mechanism in response to microcystin,
and Keap1-HKO mice showed a much higher increase in Gst and
Gpx2 mRNAs, together with higher hepatic GSH concentrations
(Figure 3).
Genes involved in microcystin uptake. Oatp transporters
have been reported to play an important role in microcystin
transport into cells [20–22]. In the present study, there was no
difference in Oatp1a1 mRNA expression before or after micro-
cystin among the three genotypes. Oatp1a4 was induced more
than 50-fold by microcystin in all three genotypes of mice, but
there was no difference between Nrf2-null and Keap1-HKO mice
(Figure 8). In comparison, although the basal expression of
Oatp1b2 (homologue to human OATP1B1 and OATP1B3) is not
different among the three genotypes of mice, microcystin induced
Oatp1b2 mRNA 5.9-fold in Nrf2-null mice, and increased 11.9-
fold in Keap1-HKO mice. Expression of Oatp2b1 showed a
similar pattern: microcystin increased Oatp2b1 approximately 3-
Figure 6. The mRNA levels of glutathione conjugation enzymes Gsta1, Gsta4, Gtsm and Gpx2 in Nrf2-null, wild-type and Keap1-HKO
mice administered saline (10 ml/kg, i.p.) or microcystin (50 mg/kg, i.p.). Livers were removed 8 h after microcystin and mRNA quantified by
RT-PCR. Values are expressed as mean 6 S.E.M. (n = 8). *Significantly different from the basal level of the same genotype (p # 0.05); #Significantly
different from Nrf2-null mice treated with microcystin (p # 0.05).
doi:10.1371/journal.pone.0093013.g006
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fold in Nrf2-null mice and wild-type mice, but 4.5-fold in Keap1-
HKO mice.
Figure 7. mRNA levels of heme oxygenase-1 (Ho-1, top) and
early growth response protein-1 (Egr1) in Nrf2-null, wild-type
and Keap1-HKO mice administered saline (10 ml/kg, i.p.) or
microcystin (50 mg/kg, i.p.). Values are expressed as mean 6 S.E.M.
(n = 8). *significantly different from the basal level of the same genotype
(p # 0.05); #significantly different from Nrf2-null mice treated with
microcystin (p # 0.05).
doi:10.1371/journal.pone.0093013.g007
Figure 8. Expression of hepatic organic anion transporting
peptide Oatp1a1, Oatp1a4, Oatp1b2, and Oatp2b1 in Nrf2-
null, wild-type and Keap1-HKO mice administered saline
(10 ml/kg, i.p.) or microcystin (50 mg/kg, i.p.). Livers were
removed 8 h after microcystin and mRNA quantified by RT-PCR. Values
are expressed as mean 6 S.E.M. (n = 8). *Significantly different from the
basal level of the same genotype (p # 0.05); #Significantly different
from Nrf2-null mice treated with microcystin (p # 0.05).
doi:10.1371/journal.pone.0093013.g008
Nrf2 Protects Microcystin Hepatotoxicity
PLOS ONE | www.plosone.org 8 March 2014 | Volume 9 | Issue 3 | e93013
Discussion
In the present study, microcystin induced acute hepatotoxicity is
evident by increased serum activities of ALT and AST, as well as
widespread liver hemorrhage and hepatocellular necrosis. Al-
though there was no statistical difference in microcystin sensitivity
between Nrf2-null mice and wild-type mice, overexpression of
Nrf2 did protect against microcystin toxicity. This is probably due
to extensive liver damage produced by this dose of microcystin
that overwhelmed the defense mechanism in wild-type mice, as
this phenomenon also occurred for the hepatotoxicity produced by
phalloidin, cadmium, bromobenzene and ally alcohol [18].
Microcystin is rapidly taken up by hepatocytes through carrier-
mediated transport. Oatp transporters, such as OATP1B1 and
OATP1B3 in human cells, have been reported to play an
important role in microcystin transport into cells [21,22], and
Oatp1b2-null mice transport less microcystin into the liver and less
liver injury is observed [20]. In the present study, there was no
significant difference in the basal expression of Oatp1a1, Oatp1a4,
Oatp1b2 and Oatp2b1 among the various Nrf2-genotypes.
Microcystin induced the expression of Oatp1a4, Oatp1b2 and
Oatp2b1, but not Oatp1a1 (Figure 8). Following microcystin
administration, higher expression of Oatp1b2 was evident in
Keap1-HKO mice, suggesting that the protection of graded Nrf2
activation against microcystin toxicity is not due to diminished
uptake of the toxicant into the hepatocytes, as in Oatp1b2-null
mice [20].
Microcystin is thought to activate the Keap1–Nrf2 pathway
through multiple mechanisms. For example, microcystin increases
the Nrf2-target genes Nqo1 and Ho-1 in NIH3T3 cells and
HepG2 cells [7], and addition of microcystin to hepatoma HepG2
and Hep3B cells results in microcystin uptake into hepatocytes and
the release of Nrf2 into the nucleus [23]. Microcystin causes
structural changes in hepatocytes by inhibiting protein phosphor-
ylase 1 and 2A, which produces further cell damage and Nrf2
activation [4]. Thus, microcystin is an activator of Nrf2 in liver,
either by microcystin at nontoxic concentration or by microcystin-
induced toxicity. Induction of Nrf2 is not a cause of microcystin-
induced toxicity, but rather an adaptive mechanism in protecting
against microcystin-induced liver injury.
The neutrophil-specific chemokine macrophage inflammatory
protein 2 (MIP-2, CXCR2) and mouse keratinocyte-derived
chemokine (mKC) are important mediators of inflammation in
acute tissue injury [24]. In the present study, microcystin-increased
MIP-2 and mKC mRNA in mice, but was much less in Keap1-
HKO mice, suggesting that constitutive activation of Nrf2 reduces
microcystin-induced liver injury by reducing chemokine activa-
tion, resulting in reduced release of inflammatory mediators.
Interleukin-1beta (1L-1b), interleukin-6 (IL-6), and tumor necrosis
factor alpha (TNFa), are important pro-inflammatory cytokines in
acute and chronic liver damage [25], and likely are involved in
microcystin-induced liver injury. In the present study, Keap1-
HKO mice had much lower expression of these cytokines after
administration of microcystin, indicating that Nrf2 reduction of
microcystin-induced liver injury could be due, at least in part, to
the reduced pro-inflammatory cytokine release in the liver.
Ho-1 and Egr-1 are two cellular protective proteins that
respond to toxic stimuli [18,26]. Induction of these acute phase
proteins would be theoretically beneficial to reduce microcystin
toxicity. However, over-expression of these proteins can also be
envisioned as a potential biomarker of increased tissue damage,
and exacerbates microcystin-induced acute hepatotoxicity. In the
present study, both Ho-1 and Egr-1 were induced markedly by
microcystin (Fig. 6). Although both genes are also considered Nrf2-
target genes [17,18], Ho-1 and Egr1 overexpression in the current
study could be considered as biomarkers of microcystin-induced
severe liver injury.
ROS play an important role in microcystin-induced acute liver
injury. Consistent with the literature, the increased lipid peroxi-
dation 8 hrs after microcystin indicates the involvement of ROS in
microcystin hepatotoxicity [5]. In combating against microcystin-
induced oxidative stress, the mRNA of GSH synthesis and
conjugating enzymes in all three genotype of mice increase, and
much more induction was seen in the Keap1-HKO mice. These
findings are in agreement with the literature regarding early
increases in the mRNAs of GSH synthesis and conjugation
enzymes in response to microcystin [9]. However, as the liver
damage progresses, the mRNAs of these GSH synthesis and
conjugation enzymes might decrease [10]. The present study
clearly shows that Keap1-HKO hepatocytes not only have a
marked activation of Nrf2, but also a lower level of ROS
production following microcystin administration. Apparently,
activation of Nrf2 protects against microcystin-induced generation
of ROS, similar to that observed for Nrf2 protection against
cadmium toxicity [16]. Taken together, GSH concentrations in
the liver (Figure 3), the mRNA for the GSH conjugation and
peroxide-reduction enzymes (Figure 7), and the mRNA for rate-
limiting enzyme for GSH synthesis Gclc (Figure 4) were expressed
at higher levels with graded Nrf2 activation in the Nrf2 ‘‘gene-
dose’’ model [16,17], not only at basal levels, but also at much
higher levels after microcystin challenge. Thus, enhancement of
GSH synthetic, conjugating and peroxide reduction enzymes
appear to be important for reducing inflammation and oxidative
stress in mice with genetic over-expression of Nrf2.
In conclusion, the present study demonstrates that Nrf2
activation decreases microcystin-induced oxidative stress and liver
injury. The protective effects of Nrf2 appear to depend on higher
expression of genes involved in antioxidant defense, particularly
the enhanced GSH synthetic, conjugation and peroxide reduction
enzymes.
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